BioSpace News Archive

Lantern Pharma Inc. today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 19, 2023, at the Mandarin Oriental in New York, NY.

Salix Pharmaceuticals today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021.

Myrtelle Inc. today announced that updated positive data from the one-year readout in the Company’s open-label Phase 1/2 First-in-Human (FIH) clinical trial for Canavan disease will be presented by Mark Hurtt, M.D. on Wednesday, October 11, 2023, at the upcoming Cell & Gene Meeting on the Mesa in Carlsbad, CA.

MAIA Biotechnology, Inc. today announced that its lead asset THIO showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor that originates from glial cells.

Biotricity, Inc. today announced its patent filing for the company’s Bioheart device.

Athersys, Inc. announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem ® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365.

Royal Philips, a global leader in health technology, and the World Stroke Organization, the world’s only global non-governmental organization focused on stroke, announced the signing of a two-year partnership aimed at improving access to high-quality stroke care.

Carmot Therapeutics, Inc. today announced preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.

Mapi Pharma Ltd. announced that recent clinical data from studies of GA Depot 40 mg will be presented at the forthcoming European Committee for Treatment and Research in Multiple Sclerosis & Americas Committee for Treatment and Research in Multiple Sclerosis meeting to take place in Milan, Italy, October 11 to 13.

Lunit (KRX:328130.KQ) today announced the presentation of 9 studies featuring its AI pathology research at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, scheduled to be held in Madrid, Spain, from October 20 to October 24, 2023.